| D&A | dilatation and aspiration; drugs and allergy |
|---|---|
| D&C | dilatation and curettage; drugs and cosmetics |
| DDA | Dangerous Drugs Act; dideoxyadenosine; digital differential analysis |
| DELIRIUM | drugs-electrolytes-low temperature and lunacy-intoxication and intracranial processes-retention of u... |
| DO | Doctor of Osteopathy (one of two fully recognized medical practioners in the US-the other being MD);... |
| New York Heart Association classification | A functional classification to assess cardiovascular disability. Class I: patients with cardiac disease without limitation of physical activity. Ordinary activity does not cause symptoms. Class II: patients with cardiac disease with slight limitation of activity; comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or angina. Class III: patients with cardiac disease producing marked limitation of activity: comfortable at rest. Less than ordinary physical activity causes symptoms. Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms may be present even at rest. (05 Mar 2000) |
|---|---|
| new zealand | A group of islands in the South Pacific Ocean. New Zealand flax. <botany> A myrtaceous shrub (Leptospermum scoparium) of new Zealand and Australia, the leaves of which are used as a substitute for tea. Source: Websters Dictionary (01 Mar 1998) |
| New Zealand mice | Inbred strains of mice, either black (NZB) or white (NZW), unique among strains used in experimental immunology because of their proclivity to spontaneous immunologic abnormalities and disorders including systemic lupus erythematosus similar to that found in humans. (05 Mar 2000) |
| investigational new drug | Status given an experimental drug after the FDA approves an application for testing it in people. (09 Oct 1997) |
| investigational new drug application | An application that must be submitted to a regulatory agency (the FDA in the united states) before a drug can be studied in humans. This application includes results of previous experiments; how, where, and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in animal studies; and how the compound is manufactured. (12 Dec 1998) |